The present invention relates to compounds of formula (I):
wherein R
1
to R
3
, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.
The present invention relates to pyrrazolo-pyrimidine derivatives of formula (I):
wherein R
1
to R
4
and A are as defined in the specification, a process for the manufacture thereof, their use for treating or preventing metabotropic glutamate receptors mediated disorders, their use for the preparation of medicaments for treating such disorders and pharmaceutical compositions containing said derivatives.
The invention relates to compounds of formula (I)
wherein R
1
, R
2
, R
3
, R
4
, R
5
and p are as defined in the description and to pharmaceutically acceptable salts thereof, to pharmaceutical compositions containing such compounds, to the manufacture of such compounds and compositions, and to methods of treating or preventing acute and/or chronic central nervous system disorders by administering such compounds.
The present invention relates to compounds of formula (I):
wherein R
1
to R
3
, A, M, L, E, G, and J are as defined in the description and claims. The invention also relates to a process for the manufacture of such compounds, pharmaceutical compositions containing them, and methods for treating CNS disorders.
Compounds as metabotropic glutamate receptor antagonists
申请人:Hoffmann-La Roche Inc.
公开号:US07504404B2
公开(公告)日:2009-03-17
The present invention relates to compounds of formula (I)
wherein A, E G, J, L, M, R1, R2, and R3 are as defined in the specification and claims. The invention also relates to pharmaceutical compositions containing such compounds and methods for preparing the compounds and compositions. The compounds are metabotropic glutamate receptor antagonists and are useful for the treatment of a variety of CNS disorders.